BIOMAT Database Logo BIOMAT Database Logo

[Surgical correction of hyperlipoproteinemia in patients with ischemic heart disease]. 1984

A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev

The experimental results obtained in 102 animals showing a beneficial effect of partial ileac bypass on hyperlipoproteinemia and experimentally-induced atherosclerosis prompted the authors to perform this surgical intervention in 34 patients with coronary heart disease (CHD) and attendant hyperlipoproteinemia resistant to therapeutic agents. The follow up period was up to five years. The patients exhibited a persistent and substantial decrease in blood lipids and atherogenic lipoproteins, a reduced incidence of angina attacks and an improved CHD course. Furthermore, the surgery resulted in a considerable and stable elevation of the cholesterol levels of antiatherogenic high density lipoproteins (by an average of 85,3%) and in a 45.8% decrease of the cholesterol coefficient of atherogenicity which contributes to atherosclerosis regression.

UI MeSH Term Description Entries
D006952 Hyperlipoproteinemia Type III An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides. Autosomal Recessive Hypercholesterolemia,Broad Beta Disease,Dysbetalipoproteinemia,Dysbetalipoproteinemia, Familial,Familial Dysbetalipoproteinemia,Familial Hypercholesterolemia with Hyperlipemia,Hypercholesterolemia, Autosomal Recessive,Hyperlipoproteinemia, Broad-beta,Hyperlipoproteinemia, Type III,Autosomal Recessive Hypercholesterolemias,Broad-beta Hyperlipoproteinemia,Hyperlipoproteinemia, Broad beta,Hyperlipoproteinemias, Type III,Recessive Hypercholesterolemia, Autosomal,Type III Hyperlipoproteinemia,Type III Hyperlipoproteinemias
D006953 Hyperlipoproteinemia Type IV A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits. Hyperprebetalipoproteinemia,Hypertriglyceridemia, Familial,Carbohydrate Inducible Hyperlipemia,Carbohydrate-Inducible Hyperlipemia,Familial Hyperlipoproteinemia Type 4,Familial Type IV Hyperlipoproteinemia,Hyper prebeta lipoproteinemia,Hyperlipoproteinemia, Type IV,Carbohydrate Inducible Hyperlipemias,Carbohydrate-Inducible Hyperlipemias,Familial Hypertriglyceridemia,Hyperlipemia, Carbohydrate Inducible,Hyperlipemia, Carbohydrate-Inducible,Hyperlipemias, Carbohydrate Inducible,Hyperlipemias, Carbohydrate-Inducible,Hyperlipoproteinemias, Type IV,Inducible Hyperlipemia, Carbohydrate,Inducible Hyperlipemias, Carbohydrate,Type IV Hyperlipoproteinemia,Type IV Hyperlipoproteinemias,Type IV, Hyperlipoproteinemia
D007082 Ileum The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008079 Lipoproteins, VLDL A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues. Pre-beta-Lipoprotein,Prebeta-Lipoprotein,Prebeta-Lipoproteins,Very Low Density Lipoprotein,Very-Low-Density Lipoprotein,Very-Low-Density Lipoproteins,Lipoprotein VLDL II,Lipoproteins, VLDL I,Lipoproteins, VLDL III,Lipoproteins, VLDL1,Lipoproteins, VLDL2,Lipoproteins, VLDL3,Pre-beta-Lipoproteins,Lipoprotein, Very-Low-Density,Lipoproteins, Very-Low-Density,Pre beta Lipoprotein,Pre beta Lipoproteins,Prebeta Lipoprotein,Prebeta Lipoproteins,VLDL Lipoproteins,VLDL1 Lipoproteins,VLDL2 Lipoproteins,VLDL3 Lipoproteins,Very Low Density Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age

Related Publications

A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev
[Hyperlipoproteinemia and ischemic heart disease].
December 1987, Vnitrni lekarstvi,
A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev
[Ischemic heart disease and hyperlipoproteinemia].
October 1973, Casopis lekaru ceskych,
A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev
[Electrocardiographic data on ischemic heart disease in hyperlipoproteinemia patients].
January 1982, Vutreshni bolesti,
A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev
[Impact of exercise on alimentary hyperlipoproteinemia in patients with ischemic heart disease].
January 1992, Kardiologiia,
A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev
[Blood lipids and lipoproteins in patients with ischemic heart disease without hyperlipoproteinemia].
January 1982, Terapevticheskii arkhiv,
A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev
Personality features of ischemic heart disease patients with different types of hyperlipoproteinemia.
January 1978, Human physiology,
A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev
[Hyperlipoproteinemia, risk indicators and ischemic heart disease].
April 1989, Vnitrni lekarstvi,
A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev
[Oral contraceptives, hyperlipoproteinemia and ischemic heart disease].
January 1978, Terapevticheskii arkhiv,
A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev
[Effect of clofibrate on glucide tolerance in patients with ischemic heart disease and hyperlipoproteinemia].
January 1978, Revista de medicina interna, neurologe, psihiatrie, neurochirurgie, dermato-venerologie. Medicina interna,
A N Klimov, and L V Lebedev, and Iu I Sedletskiĭ, and V F Triufanov, and V A Nagornev
[Blood viscosity in ischemic heart disease with different types of hyperlipoproteinemia].
June 1977, Kardiologiia,
Copied contents to your clipboard!